Drug Profile
Research programme: chondroitinases - Acorda Therapeutics
Alternative Names: Chondroitin sulfate proteoglycan lyases; Chondroitinase ABC−I; Recombinant chondroitinase AC; Recombinant chondroitinase BLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cambridge University Technical Services; Kings College London
- Developer Acorda Therapeutics
- Class Chondroitinases and chondroitin lyases; Recombinant proteins
- Mechanism of Action Chondroitin lyase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Spinal cord injuries
Highest Development Phases
- No development reported Spinal cord injuries
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Spinal-cord-injuries in USA (IV)
- 10 Apr 2012 Preclinical development is ongoing in US
- 12 Feb 2008 Acorda Therapeutics is seeking partnership opportunities for this research programme